FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT	OF	CHAN	GES	IN BE	NEFIC	IAL C	WNE	RSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BEAVER CAROLYN				ME	2. Issuer Name and Ticker or Trading Symbol MEDICINOVA INC [MNOV]							(Ch	5. Relationship of Reporting Person(s) to Is (Check all applicable) X Director 10% On			son(s) to Iss 10% Ow		
(Last)	(Fi	rst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/13/2023								Officer below)	(give title		Other (s below)	pecify
C/O MEDICINOVA, INC. 4275 EXECUTIVE SQUARE, SUITE 300					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person					
(Street)	LA CA	A	92037											Form f Persor		e than	One Repor	ting
(City) (State) (Zip) Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is interested at satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								hat is intende	d to									
		Tab	le I - Noi	n-Deriv	ative	Sec	curities	s Ac	quired, D	ispo	osed o	f, or Be	neficial	ly Owne	i			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,		Code (Ins	Transaction Dispose Code (Instr. 5)		rities Acquired (A) or ed Of (D) (Instr. 3, 4 ar		Benefici Owned I	es ally Following	Form (D) or	orm: Direct D) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
				Code V Amount (A) or (D)				r Price	Reporte Transac (Instr. 3	tion(s)			Instr. 4)					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3) 1. Transaction Date (Month/Day/Year) 2. Conversion Of Exercise (Month/Day/Year) 3. Transaction Date (Execution Date, if any (Month/Day/Year)				Date,		ransaction of code (Instr. Derivative		ve es ed	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	or Nu Date Expiration of					Amount or Number of Shares							
Stock Option (Right to Buy)	\$2.23	06/13/2023			A		20,000		(1)	06/1	12/2033	Common Stock	20,000	\$0	20,000		D	

Explanation of Responses:

1. The option vests in four equal installments on September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024, subject to continued service with the Company.

/s/ Yuichi Iwaki, attorney-in-06/15/2023 fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.